Published in J Clin Oncol on November 01, 1993
The two-week-wait cancer initiative in urology: useful modernization? J R Soc Med (2004) 3.28
Early diagnosis and staging of prostate cancer. Rev Urol (2003) 0.77
Validation of prostate-specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries. Cancer (2016) 0.75
Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med (1991) 7.21
Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst (1999) 5.92
A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology (2001) 5.16
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol (1989) 4.03
Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst (1997) 3.92
Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA (1993) 3.91
The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol (1993) 3.66
The clinical usefulness of prostate specific antigen: update 1994. J Urol (1994) 3.64
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol (1989) 3.44
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med (1994) 3.29
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst (2000) 3.27
T-DNA insertional mutagenesis for functional genomics in rice. Plant J (2000) 3.25
Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol (1999) 3.19
The management of renal angiomyolipoma. J Urol (1986) 3.05
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol (1997) 3.04
Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA (1995) 2.70
Interpreting results of prostate-specific antigen testing for early detection of prostate cancer. J Gen Intern Med (1996) 2.57
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol (1998) 2.51
The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol (2001) 2.41
Prostate-specific antigen. Improving its ability to diagnose early prostate cancer. JAMA (1992) 2.38
Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med (1991) 2.37
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med (1997) 2.25
Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet (1992) 2.15
Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol (1994) 2.10
Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology (2001) 2.09
Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med (1998) 2.05
A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch Fam Med (1993) 2.05
Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol (1991) 1.93
Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol (1994) 1.93
The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J Urol (1997) 1.88
Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res (1989) 1.86
Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N Engl J Med (1995) 1.78
Wound recurrence following conventional treatment of colorectal cancer. A rare but perhaps underestimated problem. Dis Colon Rectum (1996) 1.77
Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol (1994) 1.75
Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol (1995) 1.75
Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol (1994) 1.73
Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol (1996) 1.73
High-resolution crystal structures of delta5-3-ketosteroid isomerase with and without a reaction intermediate analogue. Biochemistry (1997) 1.71
Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil. Int J Radiat Oncol Biol Phys (1993) 1.71
Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol (1994) 1.67
The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA (1996) 1.65
Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol (1992) 1.65
Age-specific reference ranges for serum PSA. N Engl J Med (1996) 1.61
A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst (1996) 1.58
A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum (1997) 1.58
Designs for group sequential phase II clinical trials. Biometrics (1987) 1.57
Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys (1995) 1.51
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol (1990) 1.49
Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06. Int J Radiat Oncol Biol Phys (1998) 1.49
Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study. Urology (1998) 1.48
Radiation therapy for glottic cancer using 6-MV photons. Cancer (1996) 1.48
Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol (1995) 1.47
Chronic idiopathic thrombocytopenic purpura. Splenic pathologic features and their clinical correlation. Arch Pathol Lab Med (1993) 1.46
Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol (2000) 1.45
Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology (1998) 1.41
The prognostic value of the modifications of the Dukes' C class of colorectal cancer. An analysis of the NSABP clinical trials. Ann Surg (1986) 1.41
A prospective randomized comparison of epidural infusion of fentanyl and intravenous administration of morphine by patient-controlled analgesia after radical retropubic prostatectomy. Mayo Clin Proc (1992) 1.40
Impact of radiation dose and tumor size on large cell lymphoma patients in complete response after integrated CHOP-Bleo-radiation treatment protocol. Int J Radiat Oncol Biol Phys (1995) 1.40
Serum percent-free PSA does not predict extraprostatic spread of prostate cancer. Am J Clin Pathol (1998) 1.40
Long-term follow-up of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2004) 1.40
Radiation therapy for squamous cell carcinoma of the tonsil. Mayo Clin Proc (1994) 1.39
Linear accelerator sypervoltage radiation therapy: testicular tumors. Radiology (1968) 1.38
Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg (1990) 1.34
The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: characteristics of patients enrolled and not enrolled. COMS Report No. 17. Arch Ophthalmol (2001) 1.34
Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol (1995) 1.33
Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol (2001) 1.31
The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am (1997) 1.29
The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. Ann Surg (1983) 1.28
Differential diagnosis between radiation and tumor plexopathy of the pelvis. Neurology (1985) 1.28
In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology (1996) 1.27
Natural history of prostatism: factors associated with discordance between frequency and bother of urinary symptoms. Urology (1993) 1.27
New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med (1995) 1.27
Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology (1995) 1.25
Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology (1996) 1.24
Squamous cell carcinoma of the scrotum: long-term followup of 14 patients. J Urol (1991) 1.24
Age-specific reference ranges for serum prostate-specific antigen. Urol Clin North Am (1997) 1.23
The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg (1984) 1.22
Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. Arch Surg (1990) 1.21
The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol (1989) 1.20
The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol (1995) 1.19
The effect of online status on the impact factors of general internal medicine journals. Neth J Med (2006) 1.19
Sexual function of men ages 40 to 79 years: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. J Am Geriatr Soc (1995) 1.16
Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg (1989) 1.16
Effects of irradiation on cortical bone and their time-related changes. A biomechanical and histomorphological study. J Bone Joint Surg Am (1988) 1.15
Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men? Urology (1995) 1.15
The natural history of prostatism: the effects of non-response bias. Int J Epidemiol (1994) 1.12
Patterns of occult bleeding in asymptomatic colorectal cancer. Cancer (1989) 1.12
A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer (1990) 1.12
HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol (1992) 1.11
The relative prognostic value of flow cytometric DNA analysis and conventional clinicopathologic criteria in patients with operable rectal carcinoma. Dis Colon Rectum (1987) 1.11
Prostate-specific antigen and androgen deprivation therapy. World J Urol (1993) 1.10
Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol (1994) 1.09
Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology (1994) 1.08
Colorectal cancer. Dukes' stage, tumor site, preoperative plasma CEA level, and patient prognosis related to tumor DNA ploidy pattern. Arch Surg (1987) 1.08